Trial Profile
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2021
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Irritable bowel syndrome
- Focus Registrational; Therapeutic Use
- Acronyms TARGET-3; Trial 3
- Sponsors Bausch Health Companies; Salix Pharmaceuticals; Valeant Pharmaceuticals International
- 23 May 2021 Results (n=3837) of pooled post hoc analysis of assessing efficacy of 3 Phase III studies TARGET-1, TARGET-2 and TARGET-3, presented at the Digestive Disease Week 2021.
- 17 May 2021 According to a Salix Pharma media release, results of pooled post hoc analysis will be presented at Digestive Disease Week (DDW) 2021.
- 13 Oct 2020 Results of post hoc analysis assessing the subgroup of patients with a history of IBS medication use before the study presented at the 28th United European Gastroenterology Week